AXSM Quote, Financials, Valuation and Earnings

Phathom Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -250.98%. Axsome Therapeutics's return on equity of -244.32% beat Phathom Pharmaceuticals's return on equity of --.

Axsome Therapeutics has a consensus price target of $173.00, signalling upside risk potential of 41.91%. On the other hand Phathom Pharmaceuticals has an analysts' consensus of $21.63 which suggests that it could grow by 390.36%. Given that Phathom Pharmaceuticals has higher upside potential than Axsome Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.997, which suggesting that the stock is 0.342% less volatile than S&P 500. In comparison Phathom Pharmaceuticals has a beta of 0.635, suggesting its less volatile than the S&P 500 by 36.461%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Phathom Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than Phathom Pharmaceuticals quarterly revenues of $29.7M. Axsome Therapeutics's net income of -$74.9M is lower than Phathom Pharmaceuticals's net income of -$74.5M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Phathom Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 15.14x versus 5.04x for Phathom Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -103.5%. Axsome Therapeutics's return on equity of -244.32% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Axsome Therapeutics has a consensus price target of $173.00, signalling upside risk potential of 41.91%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $75.08 which suggests that it could grow by 47.31%. Given that Rhythm Pharmaceuticals has higher upside potential than Axsome Therapeutics, analysts believe Rhythm Pharmaceuticals is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.997, which suggesting that the stock is 0.342% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.300, suggesting its more volatile than the S&P 500 by 130.019%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Axsome Therapeutics's net income of -$74.9M is lower than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 15.14x versus 23.89x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -125.59%. Axsome Therapeutics's return on equity of -244.32% beat SpringWorks Therapeutics's return on equity of -46.69%.

Axsome Therapeutics has a consensus price target of $173.00, signalling upside risk potential of 41.91%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 42.5%. Given that SpringWorks Therapeutics has higher upside potential than Axsome Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.997, which suggesting that the stock is 0.342% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.323%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. Axsome Therapeutics's net income of -$74.9M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 15.14x versus 19.79x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -63.08% compared to Axsome Therapeutics's net margin of 8.48%. Axsome Therapeutics's return on equity of -244.32% beat Stryker's return on equity of 15.22%.

Axsome Therapeutics has a consensus price target of $173.00, signalling upside risk potential of 41.91%. On the other hand Stryker has an analysts' consensus of $424.43 which suggests that it could grow by 14.86%. Given that Axsome Therapeutics has higher upside potential than Stryker, analysts believe Axsome Therapeutics is more attractive than Stryker.

Axsome Therapeutics has a beta of 0.997, which suggesting that the stock is 0.342% less volatile than S&P 500. In comparison Stryker has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.393%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.88% to investors and pays a quarterly dividend of $0.84 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Axsome Therapeutics quarterly revenues are $118.8M, which are smaller than Stryker quarterly revenues of $6.4B. Axsome Therapeutics's net income of -$74.9M is lower than Stryker's net income of $546M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Stryker's PE ratio is 47.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 15.14x versus 6.31x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.